ClinicalTrials.gg
TerminatedNCT04123093Updated Dec 11, 2023Results posted

Safety and Efficacy of the Noxsano Wound Care Bandage

An interventional study of Noxsano Bandage (Healthy Volunteers) and Noxsano Bandage (Wound Care) in Wound Heal, Peripheral Artery Disease and Ulcer, Leg, sponsored by OhioHealth. Terminated at 1 site in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by OhioHealth · Not applicable, Interventional, and Other

How we know

Why this study was terminated
Due to rigorous inclusion criteria and the constraints brought on the health care system from the COVID 19 pandemic which adversely effected enrollment, the sponsor and collaborator have decided to halt enrollment and officially close out the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Enrollment
309th of 373
13 · median 64
Started
2019
with 23 others
No phase
217 of 479
40 open now
Registered
317th of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 309th largest by enrollment of the 373 interventional ones that give a count, is one of 24 that started in 2019, is one of 217 with no phase, and was the 317th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

This study is a prospective, interventional, non-randomized study designed to assess the safety and efficacy of the Noxsano Bandage (study device) in healthy subjects and wound care subjects with a diabetic lower extremity ulceration and/or arterial insufficiency lower extremity ulceration.

03

Conditions studied

  • Wound Heal
  • Peripheral Artery Disease
  • Ulcer, Leg
  • Ulcer Foot
  • Diabetic Foot Ulcer
  • Arterial Insufficiency
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Group 1: Subjects must meet all of the following criteria to be eligible for enrollment:

  1. Subject is ≥ 18 and \< 80 years of age.
  2. Subject is white, black or African American
  3. Subject has provided written .
  4. Subject is willing to comply with study follow-up requirements.
  5. Subject has intact skin on lower extremities.

Group 2: Subjects must meet all of the following criteria to be eligible for enrollment:

  1. Subject is ≥ 18 and \< 80 years of age.
  2. Subject has a baseline wound surface area of \< 25 cm2.
  3. Subject has provided written informed consent.
  4. Subject is willing to comply with study follow-up requirements.
  5. Subject with at least one of the following:

    1. Diabetic lower extremity ulceration with a (HgbA1c) value ≤ 9.0, drawn within 3 months prior to study participation , and/or
    2. Arterial insufficiency lower extremity ulceration with a post-revascularization ankle-brachial index (ABI) value of ≥ 0.40 and ≤ 0.80 on the involved extremity, performed within 3 months prior to study participation1, and/or
    3. Diabetic and/or arterial insufficiency lower extremity ulceration deemed in-eligible for revascularization with 3 months prior to study participation

Exclusion criteria

Exclusion Criteria:

Group 1: Subjects will be excluded from the trial if any of the following criteria are met:

  1. Subject is \< 18 or ≥ 80 years of age.
  2. Subject has a history of diabetes, arterial insufficiency, or osteomyelitis.
  3. Subject has a known to adhesives.
  4. Subject is on any prescription medications, including . Due to the short duration of the procedure period (3 days), subjects who initiate prescription medications during study participation will continue in the study.
  5. Subject is pregnant, plans to become pregnant during the study period, or is breastfeeding.
  6. Subject is non-English speaking or reading.
  7. Subject is unable to give . -

Group 2: Subjects will be excluded from the trial if any of the following criteria are met:

  1. Subject is \< 18 or ≥ 80 years of age.
  2. Subject has a baseline wound surface area of ≥ 25 cm2.
  3. Subject has a plantar wound.
  4. Subject with diabetes with an HgbA1c value of > 9.0, drawn within 3 months prior to study participation . Subject with arterial insufficiency with an ABI value of \< 0.40 or > 0.80, performed within 3 months prior to study participation .
  5. Subject with osteomyelitis contiguous with the ulceration treatment site.
  6. Subject with peripherally-inserted central catheter (PICC) line antibiotic treatment within the previous 6 months.
  7. Subject requiring any type of amputation on the treatment limb within 3 months prior to study participation.
  8. Subject with a known hypersensitivity to adhesives.
  9. Subject is on active therapy (does not include inhaled steroids).
  10. Subject is pregnant, plans to become pregnant during the study period, or is breastfeeding.
  11. Subject is non-English speaking or reading.
  12. Subject is unable to give informed consent.
  13. Subject is currently enrolled in another interventional study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Healthy Volunteers

    The initial phase of the study is designed to determine the safety of the study device, the Noxsano Bandage, in healthy volunteers without wounds.

    Device: Noxsano Bandage (Healthy Volunteers)

  • Experimental
    Wound care

    The second phase of the study is designed to determine the effectiveness of the study device in wound healing in subjects with active wounds.

    Device: Noxsano Bandage (Wound Care)

Interventions

  • DeviceNoxsano Bandage (Healthy Volunteers)

    Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.

  • DeviceNoxsano Bandage (Wound Care)

    Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).

06

What researchers measure

Primary outcomes

  1. Adverse Events - Healthy Volunteers

    Adverse events related to the Noxsano bandage will be assessed using a safety and adverse reactions questionnaire that includes questions for the subject regarding tolerance, side effects, and adverse events.

    Time frame: 4 weeks post-bandage removal

  2. Wound Surface Area

    Wound surface area will be measured using a horizontal and vertical measurement taken in centimeters (cm) using a standard ruler. These measurements are used to calculate wound area in centimeters squared (cm2).

    Time frame: change in baseline wound area at 2 months

Secondary outcomes

  1. Adverse Events - Wound Care Subjects

    Adverse events related to the Noxsano bandage will be assessed using a safety and adverse reactions questionnaire that includes questions for the subject regarding tolerance, side effects, and adverse events.

    Time frame: 12 months post-treatment

07

Results

Posted Dec 11, 2023

Participant flow

Phase 1
Participant flow — Phase 1
MilestoneHealthy VolunteersWound Care
Started110
Baseline visit100
Completed100
Not completed10
Withdrew: Subject did not show up for baseline visit and was replaced10
Phase 2
Participant flow — Phase 2
MilestoneHealthy VolunteersWound Care
Started02
Baseline visit02
Completed00
Not completed02
Withdrew: Physician decision01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryAdverse Events - Healthy Volunteers

Adverse events related to the Noxsano bandage will be assessed using a safety and adverse reactions questionnaire that includes questions for the subject regarding tolerance, side effects, and adverse events.

Time frame:
4 weeks post-bandage removal
Reported as:
Count of participants · Participants
Adverse Events - Healthy Volunteers
ParticipantsHealthy Volunteers
Adverse Events - Healthy Volunteers3
PrimaryWound Surface Area

Wound surface area will be measured using a horizontal and vertical measurement taken in centimeters (cm) using a standard ruler. These measurements are used to calculate wound area in centimeters squared (cm2).

Time frame:
change in baseline wound area at 2 months

No measurements were reported for this outcome.

SecondaryAdverse Events - Wound Care Subjects

Adverse events related to the Noxsano bandage will be assessed using a safety and adverse reactions questionnaire that includes questions for the subject regarding tolerance, side effects, and adverse events.

Time frame:
12 months post-treatment

No measurements were reported for this outcome.

Adverse events

Collected over Adverse event data was collected up to 4 weeks for Healthy Volunteers and up to 13 months for Wound Care participants.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Volunteers0/10 (0%)0/10 (0%)7/10 (70%)
Wound Care0/2 (0%)1/2 (50%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventHealthy VolunteersWound Care
PainSkin and subcutaneous tissue disorders0/101/2
Most frequent other events
Most frequent other events
EventHealthy VolunteersWound Care
itchy skinSkin and subcutaneous tissue disorders7/101/2
dry dkinSkin and subcutaneous tissue disorders5/101/2
painSkin and subcutaneous tissue disorders2/101/2
red skinSkin and subcutaneous tissue disorders1/101/2
swollen skinSkin and subcutaneous tissue disorders2/101/2
skin discolorationSkin and subcutaneous tissue disorders5/100/2
skin darkeningSkin and subcutaneous tissue disorders0/101/2
pressure soresSkin and subcutaneous tissue disorders0/101/2
bruiseSkin and subcutaneous tissue disorders2/100/2
skin flakingSkin and subcutaneous tissue disorders1/100/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Healthy VolunteersWound CareTotal
<=18 years000
Between 18 and 65 years909
>=65 years123
Age, Continuous
Age, Continuous(years)Healthy VolunteersWound CareTotal
Mean39.9 ± 13.469.5 ± 0.544.8 ± 16.5
Sex: Female, Male
Sex: Female, Male(Participants)Healthy VolunteersWound CareTotal
Female617
Male415
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy VolunteersWound CareTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American516
White516
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Healthy VolunteersWound CareTotal
United States10212
Body Mass Index
Body Mass Index(kilograms pre meter squared)Healthy VolunteersWound CareTotal
Mean—29.8 ± 1.029.8 ± 1.0
Height
Height(centimeters)Healthy VolunteersWound CareTotal
Mean—175.3 ± 5.1175.3 ± 5.1
Hemoglobin A1c
Hemoglobin A1c(mmol/mol)Healthy VolunteersWound CareTotal
Mean—7.8 ± 0.77.8 ± 0.7

6 further baseline measures are reported on the registry.

08

Study locations

1 site
  • OhioHealth
    Columbus, Ohio 43214, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Sep 2020, 13 months.

Results were first posted in Dec 2023, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2019
First posted
Oct 10, 2019
StartActual
Aug 9, 2019
Primary completionActual
Sep 9, 2020
CompletionActual
Sep 9, 2020
Results first posted
Dec 11, 2023
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04123093
Lead sponsor
OhioHealth
Collaborators
Noxsano, Inc.
Responsible party
Sponsor
First posted
Oct 10, 2019
Start date
Aug 9, 2019
Primary completion
Sep 9, 2020
Completion
Sep 9, 2020
Results posted
Dec 11, 2023
Last update
Dec 11, 2023

Study contacts

Mitch Silver, DO
principal investigator · OhioHealth

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion